1 completed, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Triple Negative Locally Advanced Non-resectable Breast Cancer: new trials by email Literature Review of Triple Negative Locally Advanced Non-resectable Breast Cancer trials Research Report on Triple Negative Locally Advanced Non-resectable Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors STAR0602, Sacituzumab Govitecan (SG) - Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 50 | 2025-03-24 | 2025-09-24 |
| Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer ixabepilone, ixabepilone + cetuximab - Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | Phase 2 | Completed | R-Pharm | 79 | 2008-06-01 | 2016-03-10 |
Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Cetuximab (1) · ixabepilone (1) · sacituzumab govitecan (1)
Marengo Therapeutics, Inc. (1) · R-Pharm (1)
Austria (1) · Canada (1) · Czechia (1) · France (1) · Greece (1) · Italy (1) · Poland (1) · Spain (1) · United States (1)